Vaxcyte (PCVX) has just raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate.
Recent trading has been strong, with Vaxcyte's share price at US$66.96 after a 7 day share price return of 17.68% and a year to date share price gain of 44.12%. The 1 year total shareholder return of 64.36% and 5 year total shareholder return of 175.56% point to momentum that has been reinforced by the Phase 3 OPUS 1 readout and the US$1b mix of equity and convertible note financing completed this week.
Surf 34 healthcare AI stocks that, like Vaxcyte after its OPUS 1 update and US$1b raise, are trying to turn clinical milestones and fresh funding into long term momentum.
After a sharp move on the OPUS 1 data and a US$1 billion raise, Vaxcyte now poses a simple question to investors: pay up today, or wait and hope for a cleaner entry later as the valuation case unfolds.
Most Popular Narrative: 11% Undervalued
Vaxcyte is currently trading at $66.96, while the most widely followed narrative framework anchors fair value closer to $75 and applies a 7.51% discount rate to get there. That gap puts the recent rally in context and frames the next leg of the story around execution rather than just the OPUS 1 headline.
Completion of a dedicated large scale manufacturing facility with Lonza, build out of a high volume fill finish line in North Carolina and plans to build commercial supply ahead of a possible VAX-31 launch could allow Vaxcyte to serve global demand efficiently. This may support stronger net margins and earnings if utilization is high and costs remain controlled.
See why 0 investors see Vaxcyte as 11% undervalued .
Result: Fair Value of $75 (UNDERVALUED)
Still, this underdog story for Vaxcyte could be upended if OPUS-2 or OPUS-3 data reset expectations, or if manufacturing costs run hotter than analysts model today.
Find out about the key risks to this Vaxcyte narrative .
Another View: Vaxcyte On Book Value
DCF work paints Vaxcyte as heavily undervalued, yet a simple P/B lens tells a sharper story. The stock trades at 3.6x book value compared with 2x for the wider US Biotechs group and 9.3x for closer peers, which tightens the margin for error if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed feelings about Vaxcyte after the rally and capital raise are understandable. Move quickly, stress test the assumptions, and weigh the 2 key rewards and 3 important warning signs .
Looking for more investment ideas beyond Vaxcyte?
If Vaxcyte has sharpened your focus, do not stop here. Fresh ideas often come from scanning outside your comfort zone and acting before the crowd catches on.
-
Target potential bargains by filtering for strong fundamentals and attractive entry points using the 20 high quality undiscovered gems .
-
Strengthen portfolio resilience by focusing on companies with robust finances through the list of solid balance sheet and fundamentals (25 results) .
-
Reduce sleepless nights by concentrating on steadier performers with the 31 resilient stocks with low risk scores .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PCVX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
